Today’s Water Cooler: TPP, Clinton email fallout, Our Revolution launch, durable goods, blockchain precariat, brain photos, Gutenberg bible
It’s beginning to feel as though Oracle (NYSE: ORCL) is spending as much time in the courtroom as the boardroom. Currently at the top of its docket: Oregon v. Oracle. In the original case between the tech giant and Oregon, the state claimed that the botched creation of the Cover Oregon heath insurance exchange website — a $240 million fiasco that never reached fully operational status — was founder Larry Ellison and team’s fault.
In light of its recent acquisition activity, Pfizer’s (NYSE: PFE) latest asset purchase might seem small, but it’s nevertheless significant. The company has agreed to pay up to nearly $1.6 billion to purchase several antibiotics assets from AstraZeneca (NYSE: AZN).
When your studio management greenlights Ben-Hur, one of the biggest bombs of 2016, it’s reasonable to think your parent company may have some questions to ask. That’s exactly what’s happening with Paramount, which released a remake of the classic picture that failed to click with audiences on an epic level.
Welcome to Neoliberal U!